Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exact Sciences Co. stock logo
EXAS
Exact Sciences
$53.30
-0.4%
$51.25
$39.97
$72.83
$10.10B0.982.59 million shs2.82 million shs
ICON Public Limited stock logo
ICLR
ICON Public
$147.04
+0.9%
$139.19
$125.10
$347.72
$11.87B1.151.09 million shs955,086 shs
Incyte Co. stock logo
INCY
Incyte
$71.22
+5.1%
$62.59
$53.56
$83.95
$13.79B0.672.08 million shs3.24 million shs
PPD, Inc. stock logo
PPD
PPD
$47.28
$47.27
$31.54
$47.41
$16.61B1.961.91 million shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-0.41%-2.43%-5.53%+18.66%+27.27%
ICON Public Limited stock logo
ICLR
ICON Public
+0.95%+5.25%+11.71%-20.96%-53.07%
Incyte Co. stock logo
INCY
Incyte
+5.12%+1.90%+12.49%+18.70%+14.67%
PPD, Inc. stock logo
PPD
PPD
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Exact Sciences Co. stock logo
EXAS
Exact Sciences
4.6148 of 5 stars
4.53.00.04.72.41.70.6
ICON Public Limited stock logo
ICLR
ICON Public
4.6918 of 5 stars
4.35.00.00.03.13.32.5
Incyte Co. stock logo
INCY
Incyte
4.4907 of 5 stars
2.14.00.03.13.22.53.1
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exact Sciences Co. stock logo
EXAS
Exact Sciences
2.95
Moderate Buy$70.9033.02% Upside
ICON Public Limited stock logo
ICLR
ICON Public
2.60
Moderate Buy$213.0844.92% Upside
Incyte Co. stock logo
INCY
Incyte
2.22
Hold$74.534.65% Upside
PPD, Inc. stock logo
PPD
PPD
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ICLR, PPD, INCY, and EXAS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Incyte Co. stock logo
INCY
Incyte
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$75.00 ➝ $107.00
6/3/2025
Incyte Co. stock logo
INCY
Incyte
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/3/2025
Incyte Co. stock logo
INCY
Incyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$61.00
5/27/2025
Incyte Co. stock logo
INCY
Incyte
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$72.00 ➝ $73.00
5/15/2025
ICON Public Limited stock logo
ICLR
ICON Public
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$200.00 ➝ $173.00
5/2/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$55.00 ➝ $75.00
5/2/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$52.00 ➝ $54.00
5/2/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$60.00 ➝ $66.00
5/2/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$69.00 ➝ $72.00
5/2/2025
ICON Public Limited stock logo
ICLR
ICON Public
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $155.00
5/2/2025
ICON Public Limited stock logo
ICLR
ICON Public
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $160.00
(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exact Sciences Co. stock logo
EXAS
Exact Sciences
$2.83B3.56$6.06 per share8.79$12.93 per share4.12
ICON Public Limited stock logo
ICLR
ICON Public
$8.19B1.45$14.29 per share10.29$115.44 per share1.27
Incyte Co. stock logo
INCY
Incyte
$4.41B3.12$0.55 per share128.94$17.82 per share4.00
PPD, Inc. stock logo
PPD
PPD
$4.68B3.55$1.99 per share23.71($1.21) per share-39.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-$204.15M-$5.51N/A106.60N/A-37.29%-5.29%-2.45%7/30/2025 (Estimated)
ICON Public Limited stock logo
ICLR
ICON Public
$612.34M$9.1815.439.621.869.56%11.81%6.65%7/23/2025 (Estimated)
Incyte Co. stock logo
INCY
Incyte
$32.62M$0.32263.7910.890.410.77%0.05%0.04%7/29/2025 (Estimated)
PPD, Inc. stock logo
PPD
PPD
$153.69M$1.0047.2825.982.116.11%-89.48%7.94%N/A

Latest ICLR, PPD, INCY, and EXAS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million
4/30/2025Q1 2025
ICON Public Limited stock logo
ICLR
ICON Public
$3.17$3.19+$0.02$1.90$2.03 billion$2.00 billion
4/29/2025Q1 2025
Incyte Co. stock logo
INCY
Incyte
$1.01$1.16+$0.15$0.80$996.17 million$1.05 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Exact Sciences Co. stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
ICON Public Limited stock logo
ICLR
ICON Public
N/AN/AN/AN/AN/A
Incyte Co. stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exact Sciences Co. stock logo
EXAS
Exact Sciences
0.97
2.15
1.93
ICON Public Limited stock logo
ICLR
ICON Public
0.36
1.26
1.34
Incyte Co. stock logo
INCY
Incyte
0.01
1.97
1.94
PPD, Inc. stock logo
PPD
PPD
N/A
1.23
1.23

Institutional Ownership

CompanyInstitutional Ownership
Exact Sciences Co. stock logo
EXAS
Exact Sciences
88.82%
ICON Public Limited stock logo
ICLR
ICON Public
95.61%
Incyte Co. stock logo
INCY
Incyte
96.97%
PPD, Inc. stock logo
PPD
PPD
87.82%

Insider Ownership

CompanyInsider Ownership
Exact Sciences Co. stock logo
EXAS
Exact Sciences
1.20%
ICON Public Limited stock logo
ICLR
ICON Public
44.00%
Incyte Co. stock logo
INCY
Incyte
17.80%
PPD, Inc. stock logo
PPD
PPD
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Exact Sciences Co. stock logo
EXAS
Exact Sciences
6,400188.64 million182.56 millionOptionable
ICON Public Limited stock logo
ICLR
ICON Public
41,10080.76 million46.20 millionOptionable
Incyte Co. stock logo
INCY
Incyte
2,320193.57 million159.46 millionOptionable
PPD, Inc. stock logo
PPD
PPD
26,000351.40 million344.72 millionNot Optionable

Recent News About These Companies

Patterns of Psychiatric Medication Use in Postpartum Depression

New MarketBeat Followers Over Time

Media Sentiment Over Time

Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

$53.30 -0.22 (-0.41%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$52.15 -1.15 (-2.16%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

ICON Public stock logo

ICON Public NASDAQ:ICLR

$147.04 +1.38 (+0.95%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$146.48 -0.56 (-0.38%)
As of 06/16/2025 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Incyte stock logo

Incyte NASDAQ:INCY

$71.22 +3.47 (+5.12%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$71.40 +0.18 (+0.26%)
As of 06/16/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

PPD stock logo

PPD NASDAQ:PPD

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.